Should Bacillus MB40 be used for Staphylococcus aureus nasal or skin decolonization?

Bacillus MB40 Shows Promise for S. aureus Decolonization but Lacks Guideline Support

Bacillus subtilis MB40 is a novel probiotic that demonstrated >95% reduction in S. aureus colonization in a randomized controlled trial, but it is not currently recommended in established clinical guidelines, which continue to endorse mupirocin-based decolonization strategies.

Current Guideline-Recommended Approach

The IDSA guidelines 1, 2 recommend the following hierarchy for S. aureus decolonization:

First-Line Strategy

• Nasal mupirocin 2% twice daily for 5-10 days (C-III recommendation)
• Can be used alone or combined with topical antiseptics

Enhanced Decolonization (for recurrent infections)

• Mupirocin PLUS chlorhexidine body washes for 5-14 days, OR
• Mupirocin PLUS dilute bleach baths (¼ cup per ¼ tub, 15 minutes twice weekly for 3 months)

When to Consider Decolonization

Decolonization should only be pursued when 1, 2:

• Recurrent SSTI occurs despite optimizing wound care and hygiene
• Ongoing transmission among household members persists despite hygiene measures

The Bacillus MB40 Evidence

What the Research Shows

A 2023 phase 2 RCT 3 in Thailand (n=115 S. aureus carriers) demonstrated:

• 96.8% reduction in intestinal S. aureus (p<0.0001)
• 65.4% reduction in nasal S. aureus (p=0.0002)
• No adverse effects or microbiome disruption
• Dosing: 250 mg once daily for 30 days

Safety Profile

Safety assessment 4 confirmed:

• No enterotoxin or mobile antibiotic resistance genes
• NOAEL in rats: 2000 mg/kg/day
• Well-tolerated in humans at 10×10⁹ CFU/day for 28 days

Clinical Decision Algorithm

Use Guideline-Recommended Strategies First

1. Screen for S. aureus colonization in high-risk patients (recurrent infections, pre-surgical)
2. Start with mupirocin-based decolonization as per IDSA guidelines 1, 2
3. Add chlorhexidine or bleach baths for enhanced effect if needed

Consider MB40 in Specific Scenarios

While not guideline-endorsed, MB40 may be considered 3 when:

• Mupirocin resistance is documented or suspected
• Multiple failed decolonization attempts with standard therapy
• Patient preference for probiotic over antibiotic/antiseptic approaches
• Intestinal colonization is suspected (not addressed by topical strategies)

Critical Advantages of MB40 Over Standard Therapy

MB40 addresses a fundamental gap: Current guidelines focus exclusively on nasal and skin decolonization, but emerging evidence 3, 5 shows the intestine is a major S. aureus reservoir that topical strategies cannot reach. MB40 targets this site through oral administration.

Comparative Benefits

• No antibiotic resistance development (unlike mupirocin, which has documented resistance 1)
• Preserves microbiome diversity 3 (unlike antibiotics and antiseptics)
• Targets intestinal reservoir that mupirocin cannot reach
• Lower recolonization rates based on computational modeling 6

Important Caveats

Why Guidelines Don't Include MB40 Yet

• Single phase 2 trial - needs larger phase 3 validation
• No long-term infection outcome data - the trial measured colonization, not infection rates
• Limited geographic validation - only tested in Thailand population
• Regulatory status unclear - marketed as dietary supplement, not FDA-approved drug

Practical Limitations

• 30-day treatment course vs. 5-10 days for mupirocin
• Cost and availability may be limited
• No head-to-head trials comparing MB40 to mupirocin

Preoperative Decolonization Context

For surgical patients specifically, recent guidelines 7, 8 strongly support:

• Mupirocin 2% twice daily for 5 days completed just before surgery
• Universal or targeted approach based on screening
• CHG baths the night before surgery

The 2024 ESCMID guidelines 7 showed mupirocin ± CHG reduced:

• S. aureus HAIs (RR 0.41,95% CI: 0.22-0.76)
• Deep SSIs (RR 0.21,95% CI: 0.07-0.62)
• 1-year mortality in clean procedures (HR 0.38,95% CI: 0.18-0.81)

Bottom Line Recommendation

Use mupirocin-based strategies as first-line per established guidelines 1, 2, 7. MB40 represents a promising alternative with strong mechanistic rationale and preliminary efficacy data 3, but requires additional validation before routine clinical use. Consider MB40 in mupirocin-resistant cases or after multiple decolonization failures, recognizing this is off-guideline use based on limited but compelling evidence.

The key innovation of MB40 is addressing intestinal colonization 3, 5, which may explain why traditional topical strategies have limited long-term success. However, clinical practice should follow guideline-recommended approaches until larger trials confirm MB40's impact on actual infection rates, not just colonization.